KROMATID, a pioneering force in next-generation genomic structural analysis, announced the completion of its Series C funding round, which has raised a total of $8 million, significantly exceeding its initial capital goals. The latest tranche of this round contributed $3.8 million and was spearheaded by BroadOak Capital Partners, alongside participation from both existing and new strategic investors who believe in the company’s vision.
The capital from this Series C funding will be strategically invested to enhance KROMATID’s innovative platforms dedicated to detecting chromosomal structural rearrangements—pivotal advancements in understanding genetic variations. Additionally, these funds will enable the company to scale its operations to meet the surging global demand for genomic analysis, while also fostering strategic partnerships with leading entities in the pharmaceutical and academic sectors, particularly in the realms of cell and gene therapy.
Over the upcoming 12 to 18 months, KROMATID plans to deploy this investment to not only accelerate its commercial growth but also to refine and enhance automation and throughput within its laboratory operations. The company recognizes the importance of a robust team to achieve its ambitious goals and will focus on strategic hiring across scientific, operational, and customer-facing teams. This commitment is aimed at addressing the increasing market demands and reinforcing KROMATID’s prominent leadership position in the field of genomic structural analysis.
KEY QUOTES:
“We are thrilled to have achieved our funding goal, which is a testament to the confidence our investors have in our vision and the unique capabilities of our technology. This investment enables us to scale faster, innovate further, and continue delivering the genomic insights that help bring life-changing therapies to patients.”
Jim Chomas, CEO of KROMATID
“KROMATID has built a differentiated platform that provides accurate, high-resolution analysis of genomic integrity, one of the most pressing needs in the rapidly expanding gene and cell therapy industry. We are proud to continue our partnership as they enter their next phase of growth.”
Bill Snider, Partner at BroadOak Capital Partners
